Despite market volatility, Morgan Stanley raised a number of stocks in March, including each US and global ones. Bullish calls included tech, pharmaceuticals and more, with the bank giving one share a double update. Here are five stocks updated by the investment bank: Pinduoduo Morgan Stanley upgraded Chinese e-commerce giant Pinduoduo in a March 2 memo, raising its price goal to $113 – putting the fill up 52% from its current level. The corporate, which can also be listed in the US, was said to be benefiting from a long-term consumption trend and a “structural” growth in Chinese e-commerce. The recent stock price correction provides a good entry point for Pinduoduo, Morgan Stanley analysts said. While there have been several reasons for the decline, akin to a weaker-than-expected recovery in consumption and rising geopolitical tensions, the bank believes the market can have overestimated the impact on the company. Furthermore, Morgan Stanley said Pinduoduo’s user base has “significantly” grown and user stickiness has increased. “PDD continues to be the e-commerce platform utilized by the majority of consumers who’ve cultivated price-conscious buying behavior over the past three years during Covid, and can proceed to support its long-term growth,” the bank’s analysts wrote. ACM Research Morgan Stanley awarded California-based semiconductor equipment cleansing services ACM Research a double rating from underweight to overweight. In a March 6 note, it also set a stock price goal of $13.50, or 20% of potential growth. The bank said ACM should enjoy a strong yr of growth in 2023, supported by “strong” growth in market share and a recent product launch. It also expects to develop its power semiconductor business in Europe. Morgan Stanley added that the company’s pricing power “holds up pretty much” and raised its earnings per share estimate for 2023-2024. Morgan Stanley’s meta moved the share price from equal weighting to an edge and raised the price goal to $250 – up 21%. “We are positive about META’s structural shift towards increased efficiency and (importantly) improved revenue, engagement and turnover trends,” the bank’s analysts wrote in a March 21 note. They added that Meta is healthier positioned than Google, which has not cut costs as aggressively, and Amazon, where growing retail profitability is dependent upon rising consumer spending. Harley-Davidson Bank upgraded Harley-Davidson to the overweight category, giving it a 50% price goal, almost 40% up. The corporate’s share price falling below $40 made it “too low cost” given its 3% revenue growth and 12% free money flow, according to Morgan Stanley in a March 21 memo. Sarepta Therapeutics Morgan Stanley pushed Sarepta Therapeutics to a bonus with a price goal of $187, giving the stock upside potential of 43%. Morgan Stanley believes that one of Sarepta Therapeutics’ drugs will receive accelerated approval from the Food and Drug Administration – creating a promising investment opportunity – according to a March 1 memo. — Michael Bloom of CNBC contributed to this report.(*5*)(*5*)(*5*)